Cystic Fibrosis – Pipeline Review, H2 2019
- Pages: 489
- Published: November 2019
- Report Code: GMDHC11467IDB
“Global Markets Direct’s, ‘Cystic Fibrosis – Pipeline Review, H2 2019’, provides an overview of the Cystic Fibrosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”
Scope
”
– The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis
– The report reviews pipeline therapeutics for Cystic Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Cystic Fibrosis therapeutics and enlists all their major and minor projects
– The report assesses Cystic Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Cystic Fibrosis”
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
“4D Molecular Therapeutics Inc
AbbVie Inc
Abeona Therapeutics Inc
Agile Sciences Inc
AGILeBiotics BV
Alaxia SAS
AlgiPharma AS
Antabio SAS
Arch Biopartners Inc
Arcturus Therapeutics Ltd
Armata Pharmaceuticals Inc
Arrevus Inc
Arrowhead Pharmaceuticals Inc
AstraZeneca Plc
Avidin Ltd
BioAegis Therapeutics Inc
Biolytx Pharmaceuticals Corp
Boehringer Ingelheim International GmbH
Breathe Easy Therapeutics Ltd
Calista Therapeutics Inc
Calithera Biosciences Inc
Catabasis Pharmaceuticals Inc
Celtaxsys Inc
Chiesi Farmaceutici SpA
Chrysalis Pharma SAS
Cilian AG
Corbus Pharmaceuticals Inc
CRISPR Therapeutics AG
CrowdOut Therapeutics
Cyclacel Pharmaceuticals Inc
Cyclenium Pharma Inc
Daiichi Sankyo Co Ltd
Destiny Pharma Plc
DiscoveryBiomed Inc
Druggability Technologies Holdings Ltd
Editas Medicine Inc
Eloxx Pharmaceuticals Inc
EmphyCorp Inc
EnBiotix Inc
Enterprise Therapeutics Ltd
Entrinsic Health Solutions, Inc.
Enzyvant Sciences Ltd
Errant Gene Therapeutics LLC
Evaxion Biotech ApS
Evotec SE
Exotect LLC
Feldan Therapeutics Inc
Galapagos NV
Generation Bio Corp
Genzyme Corp
Grupo Praxis Pharmaceutical SA
Helperby Therapeutics Group Ltd
Horizon Therapeutics PLC
Hypo-Stream Ltd
Icagen Inc
ID Pharma Co Ltd
Idorsia Pharmaceutical Ltd
Immun System IMS AB
Invion Ltd
Ionis Pharmaceuticals Inc
Kamada Ltd
Kither Biotech Srl
Kyorin Pharmaceutical Co Ltd
Lakewood-Amedex Inc
Lamellar Biomedical Ltd
Laurent Pharmaceuticals Inc
Lexicon Pharmaceuticals Inc
MannKind Corp
Mariposa Health Ltd
Microbion Corp
Mucokinetica Ltd
Nanogenics Ltd
Neupharma Srl
New Amsterdam Sciences Inc
Novabiotics Ltd
Novartis AG
Novoteris LLC
Omnispirant Ltd
Onspira Therapeutics Inc
Orphomed Inc
OrPro Therapeutics Inc
Oryn Therapeutics
Paranta Biosciences Ltd
Pharmaero ApS
Pharmaxis Ltd
PhaseBio Pharmaceuticals Inc
Polyphor AG
Progenra Inc
ProQR Therapeutics NV
Protalix BioTherapeutics Inc
Proteostasis Therapeutics Inc
Pulmatrix Inc
Rare Partners Srl
Recode Therapeutics Inc
Renovion Inc
ReveraGen BioPharma Inc
Riptide Bioscience Inc
Santhera Pharmaceuticals Holding AG
SciBac Inc
Sequoia Sciences Inc
Silurian Pharmaceuticals Inc
SolAeroMed Inc
Spirovant Sciences Inc
Spyryx Biosciences Inc
Synedgen Inc
Synovo GmbH
Synspira LLC
Takeda Pharmaceutical Co Ltd
TGV-Inhalonix Inc
Translate Bio Inc
Trucode Gene Repair Inc
Vast Therapeutics Inc
Vectura Group Plc
Verona Pharma Plc
Vertex Pharmaceuticals Inc
Vironika LLC
Zambon Co SpA
Zata Pharmaceuticals Inc”
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple report purchases.